BioNTech Investor Day Presentation Deck
Immunogenicity
iNeST | Autogene cevumeran (BNT122): Substantial and durable
T cell expansion observed in immune responders after BNT122 treatment
50% 50%
(n=8) (n=8)
Immune responder
Immune non-responder
Responder positive assay 1 and 2
Non-responders (n=8)
Responders (n=8)
iNeST is being developed in collaboration with Genentech.
Balachandran VP, et al. ASCO Annual Meeting 2022; Poster presentation 2516.
% of all blood T cells
Assay 1: T-cell clonal expansion by TCRVB sequencing
Responders
(n=8)
100-
10-
0 (0.0)
0 (0.0)
0.1-
0.01-
0.001-
Median % of all blood T cells (95% CI)
Pre-vaccine Post-vaccine
▪▪▪▪▪▪▪▪▪▪▪▪▪
20 40 60 80 100
Weeks after surgery
0 (0.0)
2.9 (0.2-10.4)
P value
0.001
0
NUM
Non-responders
(n=8)
mRNA cancer vaccines
20 40 60
80 100
BIONTECH
104View entire presentation